EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome

American Heart Journal

Volumn 162, Issue 4, 2011, Pages

  White, William B ^a   Bakris, George L ^b   Bergenstal, Richard M ^c   Cannon, Christopher P ^d   Cushman, William C ^e   Fleck, Penny ^f   Heller, Simon ^g   Mehta, Cyrus ^h   Nissen, Steven E ⁱ   Perez, Alfonso ^f   Wilson, Craig ^f   Zannad, Faiez ^j  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c PARK NICOLLET CLINIC   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^f TAKEDA PHARMACEUTICALS   (United States)

^g UNIVERSITY OF SHEFFIELD   (United Kingdom)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j UNIVERSITÉ DE LORRAINE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; PLACEBO;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 80053650554     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.08.004     Document Type: Article

References (17)

1. J.B. Meigs Epidemiology of cardiovascular complications in type 2 diabetes mellitus Acta Diabetol 40 suppl 2 2003 S358 361
2. Centers for Disease Control and Prevention (CDC) National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007 2008 US Dept of Health and Human Services, Centers for Disease Control and Prevention Atlanta, GA Available at: http://www.cdc.gov/diabetes/ pubs/pdf/ndfs-2007.pdf. Last accessed February 16, 2009
3. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS-33) Lancet 352 1998 837 853
4. ACCORD Study Group Long-term effects of intensive glucose lowering on cardiovascular outcomes N Engl J Med 364 2011 818 828
5. The ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
6. A.B. Goldfine Assessing the cardiovascular safety of diabetes therapies N Engl J Med 359 2008 1092 1095
7. U.S. Food and Drug Administration FDA announces new recommendations on evaluating cardiovascular risk in drugs intended to treat type 2 diabetes http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116994.htm Last accessed May 29, 2011
8. J.J. Holst, and C.F. Deacon Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes Diabetes 47 1998 1663 1670 (Pubitemid 28476238)
9. S.B. Ghatak, D.S. Patel, and N. Shanker Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus Curr Diabetes Rev 6 2010 410 421
10. W.B. White, P. Gorelick, and P. Fleck Cardiovascular events in patients receiving alogliptin: findings from a pooled analysis of randomized clinical trials (abstract) Meeting of the 70th Annual American Diabetes Association, Orlando, Florida, June 2 2010
11. K.K.G. Lan, and D.L. DeMets Discrete sequential boundaries for clinical trials Biometrika 70 1983 659 663
12. K.K.G. Lan, and D.L. DeMets Group sequential procedures: calendar versus information time Stat Med 8 1989 1191 1198 (Pubitemid 19255867)
13. J.S. Borer, H. Pouleur, and E. Abadie Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval Eur Heart J 28 2007 1904 1909 (Pubitemid 47236658)
14. A.M. Abbatecola, S. Maggi, and G. Paolisso New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies Drugs Aging 25 2008 913 925
15. S. Ahmed, C.P. Cannon, and S.A. Murphy Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results from the PROVE-IT-TIMI 22 trial Eur Heart J 27 2006 2323 2329 (Pubitemid 44453576)
16. S.D. Wiviott, E. Braunwald, and D.J. Angiolillo Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-TIMI 38 Circulation 118 2008 1626 1636
17. R. Wilcox, S. Kupfer, and E. Erdmann Effects of pioglitazone on major adverse events in high-risk patients with type 2 diabetes: results from PROspective pioglitazone Clinical Trial In macroVascular Events (PROactive 10) Am Heart J 155 2008 712 717